Addressing Compassion Fatigue as a Cost of Caring: Interview With Anita Everett, MD: Part 3
Anita Everett, MD, recent past-president of the American Psychiatric Association, discusses physician burnout and compassion fatigue.
APA 2018
Interventions to Prevent Physician Burnout: Interview With Anita Everett, MD: Part 2
Anita Everett, MD, recent past-president of the American Psychiatric Association, discusses physician burnout and compassion fatigue.
Combating Compassion Fatigue and Burnout: Interview With Anita Everett, MD: Part 1
Anita Everett, MD, recent past-president of the American Psychiatric Association, discusses physician burnout and compassion fatigue.
Electroconvulsive Therapy Effective in Children With Autism
Electroconvulsive therapy (ECT) has been used for refractory psychiatric conditions in the United States since 1938. Despite this, few practitioners are comfortable recommending ECT for minors.
Smartphone-Based Monitoring for Bipolar Depression, Mania Symptoms: Results From MONARCA II Trial
The primary outcomes assessed were the differences in clinically assessed depressive and manic symptoms, as well as the rate of depressive and manic episodes.
Brexpiprazole Effective for Long-term Adjunctive Treatment of Major Depressive Disorder
Treatment with brexpiprazole as adjunctive antidepressant therapy was safe and effective in patients with major depressive disorder.
Preliminary Virtual Reality Therapy Trial for Agoraphobia Shows Promise
The development of effective implementation could make virtual reality a serious, accessible therapy for individuals with specific phobias and other anxiety disorders.
Depression in Patients With Dementia May Increase Risk for Heart Disease
Clinicians should take depression into careful consideration when treating patients with Alzheimer dementia, as the two conditions combined may predispose patients to cardiovascular disease more than either condition alone.
Novel Buprenorphine Combination Therapy Shows Efficacy for MDD in Long-Term Trial
The average MADRS-10 scores decreased from baseline, and this decrease was maintained at the end of the study.
Deutetrabenazine Associated With Long-Term Improvements for Tardive Dyskinesia
Investigators examined the long-term efficacy of deutetrabenazine measured by Abnormal Involuntary Movement Scale, Clinical Global Impressions Scale, and Patients’ Global Impression of Change Scale in real-word clinical practice settings.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in APA 2018
Loading... 
Loading...